Anti-EIF4ENIF1 antibody produced in rabbit

EIF4ENIF1 (eukaryotic translation initiation factor 4E nuclear import factor 1) is a nucleocytoplasmic shuttling protein mainly associated with the cell growth control. It has an eIF4E (eukaryotic initiation factor 4E)-binding site, one bipartite nuclear localization signal and two leucine-rich nuclear export signals. It is localized to the nucleus of mammalian cells and is also concentrated in the processing bodies (P-bodies) i.e. mRNA decay site.

Eukaryotic translation initiation factor 4E transporter recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

The nucleocytoplasmic transport of EIF4ENIF1 (eukaryotic translation initiation factor 4E nuclear import factor 1) via nuclear pore complex (NPC) is dependent on various nuclear localization signals (NLSs), nuclear export signals (NESs). It mediates the nuclear import of eIF4E (eukaryotic translation initiation factor 4E). During the import it interacts with the importin αβ pathway in piggy-back mechanism manner. It controls the maturation of mRNA and mRNA half-life. Mutation in the gene causes Primary ovarian insufficiency (POI), a premature ovarian failure.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Corresponding Antigen APREST73540

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany